None listed
Conditions
Brief summary
Macrosomia remains a common and important complication of type 1 diabetes in pregnancy, with adverse consequences for both mother and neonate. Accurate determination of glycaemic control remains difficult due to limitations in the accuracy of indices of glycaemic control in pregnancy and ongoing controversy regarding the timing of self-monitoring of blood glucose. Continuous glucose monitoring provides accurate glycaemic data but is limited due to cost and availability. Furthermore its use has not consistently shown improvements in pregnancy outcome. We hypothesise that glycated albumin will be a useful clinical tool for monitoring glycaemic control in pregnancy and with the availability of a new automated assay, has the potential to be widely accessable and cost effective.
Interventions
Self-monitoring of blood glucose
Continuous glucose monitoring (carried out for 6 days at a time at each of the three timepoints illustrated below) and measurement of indices of glycaemic control at three timepoints throughout pregnancy (14-18 weeks gestation; 24-28 weeks gestation; 32-26 weeks gestation):
- HbA1c
- Fructosamine
- Glycated Albumin
- 1,5-anhydroglucitol
Sponsors
Northern Sydney Local Health District
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- Type 1 diabetes mellitus - 11-18 weeks of gestation - Aged > 18 years
Exclusion criteria
- Severe renal impairment - > stage 3 chronic kidney disease - Severe hepatic derangement - AST > 3 times upper limit of normal and/or ALT > 3 times upper limit of normal
Outcome results
None listed